MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.
Mitogen-activated protein kinase (MAPK) kinase (MEK) is an integral component of the RAS pathway and a therapeutic target in RAS-driven cancers. Although tumor responses to MEK inhibition are rarely durable, MEK inhibitors have shown substantial activity and durable tumor regressions when combined w...
Main Authors: | Mark Yarchoan, Aditya A Mohan, Lauren Dennison, Teena Vithayathil, Amanda Ruggieri, Gregory B Lesinski, Todd D Armstrong, Nilofer S Azad, Elizabeth M Jaffee |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0224600 |
Similar Items
-
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
by: Dylan A. Farnsworth, et al.
Published: (2022-11-01) -
Mek mulung
by: Malaysia. Kementerian Perpaduan, Kebudayaan, Kesenian dan Warisan. Jabatan Muzium dan Antikuiti, et al.
Published: ([dat) -
Mek mulung
by: Malaysia. Kementerian Kebudayaan, Belia dan Sukan. Bahagian Kebudayaan
Published: (1981) -
Insulin augments angiotensin II-induced myocardial fibrosis via the MEK/STAT3 pathway
by: Nanyu Cao, et al.
Published: (2023-12-01) -
Cancer immunotherapy : immune suppression and tumor growth /
by: Jaffee, Elizabeth M., editor, et al.
Published: (2013)